Bluefin Capital Management, LLC Arcus Biosciences, Inc. Transaction History
Bluefin Capital Management, LLC
- $1.3 Billion
- Q3 2024
A detailed history of Bluefin Capital Management, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Bluefin Capital Management, LLC holds 70,700 shares of RCUS stock, worth $991,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,700Holding current value
$991,921% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RCUS
# of Institutions
200Shares Held
51.5MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$137 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$76.7 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$48.8 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$42.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$34.2 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.01B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...